

Bcl-3 Antibody

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H	Endogenous	60	Rabbit	#P20749	602

Product Usage Information**Application**

Western Blotting
Immunoprecipitation

Dilution

1:1000
1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. *Do not aliquot the antibody.*

Specificity/Sensitivity

Bcl-3 Antibody recognizes endogenous levels of total Bcl-3 protein.

Species predicted to react based on 100% sequence homology

Mouse

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of mouse Bcl-3 protein. Antibodies are purified by peptide affinity chromatography.

Background

The NF-κB/Rel transcription factors are present in the cytosol in an inactive state complexed with the inhibitory IκB proteins (1-3). Activation occurs via phosphorylation of IκBα at Ser32 and Ser36 followed by proteasome-mediated degradation that results in the release and nuclear translocation of active NF-κB (3-7). IκBα phosphorylation and resulting Rel-dependent transcription are activated by a highly diverse group of extracellular signals including inflammatory cytokines, growth factors, and chemokines. Kinases that phosphorylate IκB at these activating sites have been identified (8). Bcl-3 is an atypical member of the IκB family. Unlike the classic IκB family members, Bcl-3 associates with p50/NF-κB1 or p52/NF-κB2 homodimers in nuclei and modulates transcription in a context-dependent manner (9,10). It is also involved in a recurring translocation, t(14;19)(q32;q13), found in some patients with B-cell chronic lymphocytic leukemia (B-CLL) and lymphoma (11,12).

Background References

1. Baeuerle, P.A. and Baltimore, D. (1988) *Science* 242, 540-6.
2. Beg, A.A. and Baldwin, A.S. (1993) *Genes Dev* 7, 2064-70.
3. Finco, T.S. et al. (1994) *Proc Natl Acad Sci USA* 91, 11884-8.
4. Brown, K. et al. (1995) *Science* 267, 1485-8.
5. Brockman, J.A. et al. (1995) *Mol Cell Biol* 15, 2809-18.
6. Traenckner, E.B. et al. (1995) *EMBO J* 14, 2876-83.
7. Chen, Z.J. et al. (1996) *Cell* 84, 853-62.
8. Karin, M. and Ben-Neriah, Y. (2000) *Annu Rev Immunol* 18, 621-63.
9. Schuster, M. et al. (2013) *Cell Commun Signal* 11, 23.
10. Annemann, M. et al. (2016) *Immunol Lett* 171, 26-35.
11. Michaux, L. et al. (1997) *Cancer Genet Cytogenet* 94, 36-43.
12. Soma, L.A. et al. (2006) *Hum Pathol* 37, 218-30.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

KARPAS cell line source: Dr. Abraham Karpas at the University of Cambridge.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.